Canakinumab, a human monoclonal antibody targeting IL-1β, is associated with the reduction of serum C-reactive protein level and the improvement of overall mortality in COVID-19; case reports showed that canakinumab can reduce the risk of recurrence of systemic disease-related pericarditis (115, 116). This evidence concerns the gene CRP and pericarditis.